A new report says Alabama's HIV and AIDS rate has dropped slightly, but its rates of chlamydia and gonorrhea have gone up.
The report from the Center for Demographic Research at Auburn University at Montgomery says there were 12.27 people per 100,000 diagnosed with HIV/AIDS in 2012. That's down from 13.75 in 2011. A similar decline occurred with the diagnosis of syphilis, which went from 15.55 per 100,000 people in 2011 to 14.85 in 2012.
More than 25,000 people are gathering in Washington, D.C. this week for the 19thAnnual International AIDS Conference. It’s the first time in more than 20 years that the U.S. will host the conference.
“The reason that the U.S. could not have the conference is because we had a ban on allowing people who are HIV-positive into the United States,” says Kathie Hiers, CEO of AIDS Alabama. “And we were one of the few countries that had that ban.”
Dr. Lisa Sterman holds up a Truvada pill at her office in San Francisco in May. Even before the Food and Drug Administration's approval, Sterman had prescribed Truvada for about a dozen patients at high risk for developing AIDS.
The Food and Drug Administration has given the first OK for a drug to prevent HIV infection.
The daily pill Truvada, made by Gilead Sciences, combines two medicines that inhibit the reproduction of HIV. It's been a mainstay in the treatment of HIV/AIDS for years, and as of today is an approved option for reducing the risk of HIV infection for people at high risk.